



**FTSE  
RUSSELL**  
An LSEG Business

## Alkermes plc (USA): Demerger of Mural Oncology (USA)

### Changes in Russell Equal Weight Index Series

10 November 2023

Subject to the completion of the demerger of Mural Oncology (USA, non-constituent) from Alkermes plc (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	16 November 2023

\*Based on the demerger terms of 1 share of Mural Oncology for every 10 shares of Alkermes plc.

\*\*Following the completion of the demerger, the ICB classification for Mural Oncology will be changed to 20103010-Biotechnology, effective from the start of trading 20 November 2023.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at [lseg.com/ftse-russell](https://lseg.com/ftse-russell)

[Terms of Use](#) | Copyright © 2023 FTSE Russell